Drug Trial Radar · NCT04557956
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Aug 19, 2021
Primary completion
Oct 15, 2025
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.
Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
Interventions
Biopsy ProcedureProcedure
Undergo tumor biopsy
Computed TomographyProcedure
Undergo CT scan
Dabrafenib MesylateDrug
Given PO
Echocardiography TestProcedure
Undergo ECHO
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Tazemetostat HydrobromideDrug
Given PO
Trametinib Dimethyl SulfoxideDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (Phase I)Time frame: The DLT observation window is 30 days
- Median Progression-free Survival (PFS) (Phase II)Time frame: At 6 and 12 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center-South County
St Louis, Missouri
Siteman Cancer Center at Christian Hospital
St Louis, Missouri
Wake Forest University Health Sciences
Winston-Salem, North Carolina
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.